Mika Kontro

机构：University of Helsinki, Helsinki University Hospital, Institute for Molecular Medicine Finland, HiLIFE – Elämäntieteiden Instituutti, Finnish Cancer Institute · ORCID：0000-0001-6353-0664

发表论文 250 篇 · 总被引 3145 次 · h-index 26

代表论文

• Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments (2025 · Journal of Internal Medicine · 被引 7)
• Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML (2026 · Cell stem cell · 被引 4)
• Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study (2025 · Blood · 被引 4)
• Predictors of response and rational combinations for the novel MCL ‐1 inhibitor MIK665 in acute myeloid leukemia (2025 · Molecular Oncology · 被引 4)
• Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemia (2025 · npj Digital Medicine · 被引 3)
• Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy (2026 · HemaSphere · 被引 2)